Growth Metrics

Merck (MRK) Net Cash Flow (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -158.09%
Dec 31, 2025 -135.31%
Sep 30, 2025 1,085.19%
Jun 30, 2025 78.22%
Mar 31, 2025 -372.78%
Dec 31, 2024 -133.20%
Sep 30, 2024 -47.77%
Jun 30, 2024 625.82%
Mar 31, 2024 43.47%
Dec 31, 2023 -162.49%
Sep 30, 2023 178.22%
Jun 30, 2023 -29.51%
Mar 31, 2023 -372.52%
Dec 31, 2022 -41.80%
Sep 30, 2022 33.84%
Jun 30, 2022 188.45%
Mar 31, 2022 128.73%
Dec 31, 2021 -219.49%
Sep 30, 2021 -10.14%
Jun 30, 2021 205.38%
Mar 31, 2021 -1,916.47%
Dec 31, 2020 101.95%
Sep 30, 2020 -291.60%
Jun 30, 2020 194.28%
Mar 31, 2020 1.03%
Dec 31, 2019 -292.57%
Sep 30, 2019 188.77%
Jun 30, 2019 -1,683.33%
Mar 31, 2019 -55.88%
Dec 31, 2018 -91.99%
Sep 30, 2018 134.19%
Jun 30, 2018 161.68%
Mar 31, 2018 3.29%
Dec 31, 2017 -5,166.67%
Sep 30, 2017 100.89%
Jun 30, 2017 -181.54%
Mar 31, 2017 644.05%
Dec 31, 2016 -172.87%
Sep 30, 2016 138.17%
Jun 30, 2016 -411.45%
Mar 31, 2016 -14.31%
Dec 31, 2015 72.01%
Sep 30, 2015 289.60%
Jun 30, 2015 -144.96%
Mar 31, 2015 123.15%
Dec 31, 2014 -289.13%
Sep 30, 2014 131.21%
Jun 30, 2014 -3,607.47%
Mar 31, 2014 -88.98%
Dec 31, 2013 257.43%
Sep 30, 2013 -146.16%
Jun 30, 2013 1,032.62%
Mar 31, 2013 93.88%
Dec 31, 2012 -777.40%
Sep 30, 2012 -72.40%
Jun 30, 2012 75.67%
Mar 31, 2012 269.94%
Dec 31, 2011 -132.95%
Sep 30, 2011 278.43%
Jun 30, 2011 -16.36%
Mar 31, 2011 -47.13%
Dec 31, 2010 6.55%
Sep 30, 2010 256.13%
Jun 30, 2010 138.81%
Mar 31, 2010 93.26%
Dec 31, 2009 -233.71%
Sep 30, 2009 47.04%
Jun 30, 2009 270.77%